18 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS completes merger with Edge Therapeutics Further to its announcement 26 November 2018, NetScientific plc (AIM: NSCI) is pleased to announce that PDS Biotechnology Corporation, a privately-held Portfolio Company which focuses on late clinical-stage cancer immunotherapy company, and Edge Therapeutics, Inc. (Nasdaq: EDGE) have completed their all share merger and that trading of the …
RNS Announcements
Orderly wind up of Wanda and Vortex
18 March 2019 NetScientific plc (“NetScientific” or the “Company”) Orderly wind up of Wanda and Vortex Further to its announcement and circular to shareholders (“Circular”) on 15 February 2019, NetScientific plc (AIM: NSCI) announces that the directors of each of Vortex Biosciences (“Vortex”) and Wanda, Inc. (“Wanda”), which are Portfolio Companies of NetScientific, have resolved to effect the orderly wind up of …
Share Price Movement
14 March 2019 NetScientific plc (“NetScientific” or the “Company”) Share Price Movement NetScientific plc (AIM: NSCI) notes its recent share price movement and confirms that it is not aware of any reason for such movement. Furthermore, the Company notes, that despite the increase in share price over recent days, the current share price still represents a substantial discount to the share price prior …
Results of General Meeting
Further to the announcement on 1 March 2019, NetScientific plc (AIM: NSCI) announces that at the general meeting held earlier today a vote to adjourn the meeting indefinitely was duly passed. Further announcements will be made as appropriate. For more information, please contact: NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO Tel: +44 (0)20 3514 1800 WH Ireland Limited (NOMAD, Financial …
Holding(s) in Company
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:NetScientific PLCLEI: 213800N5WD46G1Y7I4581b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer2. Reason for …
Holding(s) in Company
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:NetScientific PLC1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer2. Reason for the …
Holding(s) in Company
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:NetScientific PLC1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer2. Reason for the …
Holding(s) in Company
Mon, 18th Feb 2019 16:54RNS Number : 4056QNetScientific PLC18 February 2019 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:NETSCIENTIFIC PLC1b. Please indicate if the issuer is a non-UK …
Glycotest Inc. Receives $3 Million Initial Tranche from $10 Million Series A Financing
London, UK – February 14, 2019 – Further to its earlier related announcement on 22 October 2018, NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company Glycotest Inc. has received the initial $3m tranche of the $10m Series A financing round with Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”), a leading healthcare group based in China. …
PDS Biotechnology Enters into Merger Agreement with Edge Therapeutics to Form NASDAQ-Listed Clinical-Stage Cancer Immunotherapy Company
Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …
Vortex Biosciences paves the way forward in CTC enumeration by introducing impedance measurements
London, UK – 08 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has presented a study that demonstrates the feasibility of combining its technology with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs). The study presented at NanoBiotech Montreux 2018 introduces the coupling of Vortex technology with …
Vortex Biosciences and STRATEC GmbH announce global partnership to scale-up manufacturing for liquid biopsy platform
London, UK – 1 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has entered into a global manufacturing agreement with STRATEC Consumables GmbH (“STRATEC”) to produce a customised chip, a crucial component of Vortex’s automated liquid biopsy platform (VTX-1). STRATEC will also assist Vortex with scale-up to commercialisation with a view …
Glycotest Inc. Completes $10 Million Series A Financing with Fosun Pharma
The following amendments have been made to the ‘Glycotest Completes $10m Series A Round with Fosun’ announcement (RNS Number: 6823E) released on 22 October 2018 at 07:00AM: The following sentence: Upon satisfaction of the contingent ODI approval, NetScientific’s controlling interest will be 50.4% of Glycotest Inc. calculated on a fully-diluted basis following the closing of the Series A Financing. Has been …
NetScientific Interim Results for the six months ended 30 June 2018
NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Interim Results for the six months ended 30 June 2018 London, UK – 28 September 2018: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces its interim results for the six months ended 30 June 2018. Financial highlights Loss after tax of £4.6m (H1 2017: loss £5.2m) …
ProAxsis Immunoassays Selected for Large-Scale ERS-Funded BRIDGE Respiratory Trial
– 1,000 patient BRIDGE study to be funded by the European Respiratory Society London, UK – 20 September, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis Limited (“ProAxsis”) has had two products selected for inclusion in the BRIDGE study*, a major upcoming clinical trial funded by the European Respiratory Society (ERS). The …
Wanda launches new digital health app Wanda CareLink™ with enhanced real-time capabilities on iOS and Android devices
London, UK – August 15, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has launched its new digital health application Wanda CareLink™. This application allows the Wanda Patient Management solution to be used on a wide variety of …
ProAxsis strengthens respiratory diagnostic portfolio by receiving CE Mark for third respiratory immunoassay
– ProteaseTag® Active Proteinase-3 Immunoassay aimed at researchers studying COPD, cystic fibrosis, and bronchiectasis London, UK – 02 August, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis Limited (“ProAxsis”) has successfully registered a CE Mark for its novel ProteaseTag® Active Proteinase-3 Immunoassay, which has been accompanied by an immediate first commercial sale of …
Change of Adviser
London, UK – 2nd August 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, is delighted to announce the appointment of WH Ireland Limited as its Nominated Adviser and Sole Broker with immediate effect. # # # For more information, please contact: NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO Tel: +44 (0)20 3514 1800 …
Portfolio Company, Wanda Enhances Remote Patient Monitoring Platform with Improved Patient Adherence Features
London, UK – July 18th, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda’s existing platform had been shown …
Grant of Options to Directors
London, UK – 26th June 2018 – NetScientific plc (AIM:NSCI) (the “Company”), the transatlantic healthcare IP commercialisation Group, today announced that on 21st June 2018, options over ordinary shares of 5p each were granted to its CEO François Martelet and CFO Ian Postlethwaite as detailed below (the “New Options”). Director Number of Options Granted Total Number of Options Held Francois Martelet 300,000 1,059,020 …
Result of AGM
London, UK – 21st June 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that all resolutions proposed at today’s Annual General Meeting, were duly passed. # # # For more information, please contact: NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO Tel: +44 (0)20 3514 1800 Consilium Strategic Communications Mary-Jane Elliott / Jessica …
NetScientific portfolio company Vortex Biosciences appoints Bob Englert as Chief Executive Officer
London, UK – 6th June 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company Vortex Biosciences has appointed Bob Englert as Chief Executive Officer. Bob, who is currently Chief Technology Officer, takes up the position with immediate effect, replacing Gene Walther, who has been Chief Executive Officer of Vortex Biosciences since January 2016. Gene has …
ProAxsis Winner of Innovative Business of the Year Award in Northern Ireland
London, UK – June 4th, 2018 – NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis has been granted the Innovative Business of the Year award at the Business Eye First Trust Awards (BEFTAs), an award for small businesses in Northern Ireland. The award, issued by First Trust Bank, saw ProAxsis emerge the elected winner amongst …
ProAxsis Awarded Invest NI Grant for Development of New ProteaseTag® Products
London, UK – June 1st, 2018 – NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis has been awarded a grant by Invest Northern Ireland to support the development of its proprietary ProteaseTag® technology to identify and quantify active protease biomarkers. The project will assist in the clinical validation of new therapeutics for deubiquitinases (DUBs) …
Notice of AGM and Annual Report & Accounts
London, UK – 22nd May 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2017 and Notice of Annual General Meeting have been sent to shareholders today and are available on the Company’s website in the Investor Relations section …
Significant Reduction in Re-Admissions of High-Risk CHF Patients Achieved by Wanda and Partner HRS
London, UK – May 21st, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda and Health Resource Solutions (HRS), Wanda’s partner, have successfully achieved a reduction of 46% in the number of hospitals re-admissions in their high-risk Congestive Heart Failure patient population. Wanda’s real-time technology continuously assesses patient status and allows for detection of adverse events up to …
ProAxsis to Present New Data Underscoring the Importance of Neutrophil Elastase in COPD at ATS 2018
London, UK – May 2nd 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. ProAxsis will be presenting data on NEATstik®, its novel point of care test for monitoring active neutrophil elastase (NE) in chronic respiratory disease. The data demonstrated that NEATstik® can identify patients with elevated active NE concentrations which could be …
Directors Dealing
18 April 2018 NetScientific plc Directors Dealing Notification NetScientific plc (AIM:NSCI) (the “Company”), the transatlantic healthcare IP commercialisation group, announces that on 17 April 2018 it received notification that Sir Richard Sykes, Barry Wilson, and Steve Smith (the “Directors”), subscribed for New Ordinary Shares (the “Shares”) in the NetScientific Placing and Subscription (the “Placing”) at a price of 52.5 pence per Share, …
Vortex Biosciences to Present Compelling Liquid Biopsy Data in Collaboration with Stanford University School of Medicine and UCLA at AACR 2018
Data demonstrate the use of circulating tumour cells for identifying clinical biomarkers, such as EGFR mutations and PD-L1 expression, in patients with Non-Small Cell Lung Cancer (NSCLC) London, UK – 16 April 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is presenting compelling new data at the …
Upcoming Investor Conferences
BioTrinity – Panel: AIM v NASDAQ v European Listing – What’s best for you – London (24 April) Approaching the 12th consecutive year, the goal of BioTrinity is to create an ideal network and partnering platform for the global life sciences industry under one roof, ultimately to help shape our healthcare future. The theme for BioTrinity 2018 is ‘Next Generation Healthcare’ which will …
NetScientific Full Year Results for the year ended 31 December 2017
NetScientific plc (“NetScientific” or the “Group”) NetScientific Full Year Results for the year ended 31 December 2017 London, UK – 29 March 2018 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, announces its full year audited results for the year ended 31 December 2017[1] Financial highlights (including post-period end highlights) Narrowed losses after tax to £9.4 million …
Health Resource Solutions (“HRS”) is expanding utilization of Wanda’s Telehealth and Predictive Analytics to Orthopedics
London, UK – March 19th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda Health, its portfolio company, is expanding into orthopedics through a new partnership with HRS Home Health (“HRS”). Wanda’s predictive analytics and artificial intelligence solutions already provide remote management solutions for chronic conditions in heart and respiratory health. The partnership with HRS, a Wanda …
Vortex Biosciences and BioView Announce Collaboration for Clinical Biomarker Identification on Circulating Tumor Cells
London, UK – 13 March 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a collaboration with BioView Ltd (TASE:BIOV), a provider of automated cell imaging and analysis solutions. The collaboration will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact CTCs from blood samples …
ProAxsis reaches the commercialisation stage of its technology by reporting its first NEATstik sale
London, UK – February 15th 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, provides an update on its portfolio company ProAxsis, which today announces its first sale of NEATstik®, the company’s point-of-care test for measuring neutrophil elastase, to a research laboratory conducting a respiratory clinical trial for a pharmaceutical company. NEATstik® was registered with a CE Mark in the second …
Publication in Nature Scientific Reports Describes Potential of Vortex Technology in Personalised Medicine for Lung Cancer patients
London, UK – 09 February 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a report published by Nature Scientific Reports. The peer reviewed report, titled “Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer” describes the use of the Vortex’s technology in capturing circulating tumour cells (CTCs), …
NetScientific Portfolio Update
London, UK – 16 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces an update on its core portfolio. Over 2018 NetScientific will continue the commercial and corporate development of all its portfolio assets to maximise value. Glycotest: Glycotest successfully completed a clinical evaluation of its HCC Panel for Hepatocellular Carcinoma (HCC), the most common form of liver cancer. …
ProAxsis Achieves CE Mark and Launches its ProteaseTag® Active Plasmin Immunoassay
London, UK – January 8th 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, provides an update on its portfolio company ProAxsis, which today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay, which has potential application in a broad range of disease indications including lung disorders. The Active Plasmin Immunoassay is the first CE-Marked …
Glycotest™ Successfully Completes Clinical Diagnostic Evaluation in Liver Cancer
London, UK – 04 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company Glycotest has successfully completed a clinical evaluation of its diagnostic panel to detect Hepatocellular Carcinoma (HCC), the most common form of liver cancer, in China. In a blind evaluation of 149 HCC positive patients and control samples, Glycotest’s HCC Panel achieved an AUROC* …
Wanda is awarded two patents which increase its ability to detect adverse event scenarios for patients
London, UK – December 12th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of two new patents exclusively licensed to its portfolio company, Wanda. The patents will significantly extend protection for the core technology used in Wanda’s software application for remote health and patient management. The patents, titled, “Apparatus, System, …
ProAxsis Announces Sales Acceleration of its CE Marked Active Neutrophil Elastase Immunoassay
London, UK – 21 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes the announcement by its portfolio company, ProAxsis, which today provides an update on sales of its ProteaseTag® Active Neutrophil Elastase Immunoassay (NEIA). ProAxsis forecasts direct sales of the NEIA to increase by a factor of three in the H2 2017 period compared to H1 2017 and …
Vortex Biosciences Announces First Commercial Sale of the VTX-1 Liquid Biopsy System
London, UK – 7 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, today announced its first direct commercial sale of its VTX-1 Liquid Biopsy System, a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs). Vortex’s VTX-1 Liquid Biopsy System automates the capture and collection of viable CTCs directly …
Health Resource Solutions Expands Use of Wanda to All Patients
London, UK – November 3rd 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that HRS Home Health (HRS) is expanding their use of Wanda to all of their home health patients. This follows a successful trial evaluation involving high-risk, co-morbid Congestive Heart Failure patients. Commenting on the news, NetScientific’s Chief Executive Officer and Chairman of Wanda, Francois R. …
Glycotest™ Further Strengthens its Intellectual Property Portfolio with an Allowed Chinese Patent
London, UK – 02 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a Chinese patent exclusively licensed to one of its portfolio companies, Glycotest, has been allowed. The patent provides broad protection of the assays in Glycotest’s HCC Panel test for early-stage hepatocellular carcinoma (HCC) and the Company’s pipeline tests for liver fibrosis and other serious liver …
Vortex Biosciences Announces Publication of Liquid Biopsy Study in Nature Partner Journals Genomic Medicine
London, UK – 1 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update from its portfolio company, Vortex BioSciences, which today announced the publication of “Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection” in Nature Partner Journals (npj) Genomic Medicine on 1 November 2017. Source: https://tinyurl.com/ybhuzpu4 DOI Number: 10.1038/s41525-017-0034-3 The peer-reviewed …
ProAxsis to Showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
London, UK – October 30th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes the announcement by portfolio company ProAxsis, that it will be presenting further data on its ProteaseTag® technology in two poster sessions at the North American Cystic Fibrosis Conference, which takes place between November 1st – 5th in Indianapolis. The first paper, concerning sputum storage, enables an …
ProAxsis to initiate clinical trial partnership with National Jewish Health for its ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease Patients
London, UK – October 27th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, provides an update on its portfolio company ProAxsis, which today announces that it has entered into a clinical trial partnership with National Jewish Health (“NJH”), the leading respiratory hospital in the United States. Under the agreement ProAxis and NJH will work together in validating ProAxsis’ ProteaseTag® point-of-care …
Directorate Change
London, UK – 25 October 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that Jonathan Paisner, Non-Executive Director, will be stepping down from his position on the Board with immediate effect, with the 25th October as his final day. Commenting on the news, Francois Martelet, Chief Executive Officer of NetScientific said: “The Board of Directors and I would like …
Glycotest™ Strengthens its Intellectual Property Portfolio with a Granted Japanese Patent
London, UK – 05 October 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a Japanese patent exclusively licensed to one of its portfolio companies, Glycotest, has been granted. The patent protects fucosylated kininogen—a key biomarker in the Glycotest’s lead HCC Panel test for early-stage liver cancer. This patent expands Glycotest’s patent portfolio which has 10 previously granted …
Wanda Awarded US Patent which Extends Protection across the US
London, UK – October 2nd 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of a new patent exclusively licensed to its portfolio company, Wanda. The patent will significantly extend protection for the core technology used in Wanda’s software application for remote health and patient management. The patent, titled, “Context-aware prediction …
NetScientific Interim Results for the six months ended 30 June 2017
NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Interim Results for the six months ended 30 June 2017 London, UK – 28 September 2017: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces its interim results for the six months ended 30 June 2017. Operational highlights First successful exit for NetScientific following sale of …
ProAxsis Appoints Diagenics Limited as Sales Distributor for the UK and Ireland
London, UK – September 14th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. ProAxsis today announces that it has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great Britain and Ireland. The appointment is expected to accelerate the commercial uptake of ProAxsis’ technology, increasing near-term sales …
ProAxsis signs partnership with a large US based biotechnology company
London, UK – September 11th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. ProAxsis today announces that it has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its novel ProteaseTag® technology. The unnamed partner is a large biotechnology company, headquartered in the US with a focus …
Notice of Interim Results
London, UK – 7 September 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that it will report its financial results for the 6 months ended 30 June 2017 on Thursday 28 September 2017. Francois Martelet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will hold a presentation and conference call for analysts on the day of results …
ProAxsis is awarded a European CE Mark for their NEATstik® point-of-care lung inflammation monitoring test
London, UK – September 4th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. ProAxsis today announced that the product development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, is complete and, having successfully registered the product with a CE Mark, ProAxsis is now able to initiate sales of …
ProAxsis awarded a Significant Innovate UK Grant
London, UK – July 24th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited has now gained further support for its ProteaseTag® technology through a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has been awarded a grant to support …
PDS Biotechnology Announces Clinical Collaboration with Merck & Co., Inc.
London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …
Glycotest™ Strengthens its Intellectual Property Reach by Expanding its United States, European and Australian Patent Portfolio
London, UK – 07 July 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a European patent exclusively licensed to one of its portfolio companies, Glycotest, has been granted. In addition, United States and Australian patents have been allowed. These patents will significantly extend protection for Glycotest’s core technology for early detection of life threatening liver disease. These …
Glycotest Update
London, UK – June 26th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, provides an update on the series A fundraising being undertaken by its portfolio company Glycotest, a US-based diagnostics company, as outlined in the Circular issued to shareholders following the Company’s placing and subscription of new shares on 26 May 2017 (the “Circular”). The Company continues …
Results of AGM
RNS Number : 7628I NetScientific PLC 21 June 2017 NetScientific plc (“NetScientific” or the “Company” or the “Group”) Result of Annual General Meeting London, UK – June 21st 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that all resolutions proposed at today’s Annual General Meeting, were duly passed. # # # For more information, please contact: …
Holding(s) in Company
RNS Number : 3190I NetScientific PLC 16 June 2017 The following is to be read in replacement of the Holdings In Company announcement released on 15 June 2017 at 14:52 under RNS number 2326I. The following sections of the notification have been amended: 7.Threshold(s) that is/are crossed or reached For filings with the FCA include the annex For filings with …
Notice of AGM and Annual Report & Accounts
NetScientific plc 170526 Annual Report and AGM (Final) (“NetScientific” or the “Company” or the “Group”) Notice of AGM and Annual Report & Accounts London, UK – May 26th 2017 – London, UK – May 26 th 2017 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation Group announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts …
Netscientific business Vortex Bio kicks off lung cancer proof of concept trial
04:18 24 May 2017 http://www.proactiveinvestors.com/companies/news/178249/netscientific-business-vortex-bio-kicks-off-lung-cancer-proof-of-concept-trial-178249.html These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs). Vortex aims to collect circulating turmour cells NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC). These studies are …
Proactive Investors One2One Investor Forum – London – June 15th 2017
Proactive Investors One2One Investor Forum – London Redx Pharma Plc | Summit Therapeutics PLC | Netscientific PLC http://www.proactiveinvestors.com/register/event_details/104 Jun 15th 2017, 6.00 pm – Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details …
Netscientific Announces that successful license by portfolio company ProAxsis of additional intellectual property from The Queen’s University of Belfast
download PDF London, UK – 10 May 2017 – NetScientific Plc (AIM: NSCI, “NetScientific”, “the Group”), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company ProAxsis has secured a second licensing agreement with the Queen’s University of Belfast for exclusive intellectual property rights for its ProteaseTag® technology. ProAxsis develops point of care diagnostics for the capture, detection and measurement of active protease …
Executed Warrants
RNS Number : 0278S NetScientific PLC 16 December 2016 (“NetScientific” or the “Company” or the “Group”) NetScientific Executed Warrants in Portfolio Company, PDS Biotechnology, a new paradigm in cancer immunotherapy London, UK – 16 December 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that it has exercised warrants for 1,387,480 shares in its portfolio company, PDS Biotechnology. The total price …
Netscientific: Vortex Biosciences Analysis Data
RNS Number : 5206P NetScientific PLC 18 November 2016 (“NetScientific” or the “Company” or the “Group”) Portfolio Company Vortex Bioscience’s circulating tumour cell (CTC) technology used in analysis demonstrating the value of combining CTCs and circulating free DNA (cfDNA) Demonstrates the Value of Combining CTCs and cfDNA in Assessing Cancer Patient Disease London, UK – November 18 – NetScientific plc (AIM:NSCI), the transatlantic healthcare …
Vortex Gains CE Mark and FDA Class 1 Registration
RNS Number : 2980O NetScientific PLC 03 November 2016 (“NetScientific” or the “Company” or the “Group”) Portfolio Company Vortex Biosciences Gains CE Mark and registers Class 1 Medical Device with FDA London, UK – November 3 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company, Vortex Biosciences, has been awarded a CE Mark for its proprietary Circulating Tumour Cell (CTC) …
Vortex Biosciences Appoints Non-Executive Director
RNS Number : 5249N NetScientific PLC 26 October 2016 (“NetScientific” or the “Company” or the “Group”) Portfolio Company Vortex Biosciences Appoints Deborah Neff ex Chief Operating Officer of Complete Genomics Inc as Non-Executive Director London, UK – October 26 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company, Vortex Biosciences, has appointed Deborah Neff as a Non-Executive Director to …
ProAxsis Gains CE Mark for its Respiratory Test
RNS Number : 2638L NetScientific PLC 30 September 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”) ProAxsis Gains CE Mark for its Respiratory Test – CE Mark allows ProAxsis to begin commercialisation in Europe London, UK – 30 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, ProAxsis, has successfully registered a CE …
NetScientific Interim Results
RNS Number : 8784K NetScientific PLC 27 September 2016 NetScientific plc (“NetScientific” or the “Group”) NetScientific Interim Financial Information for the six months ended 30 June 2016 London, UK – 27 September 2016: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces its interim results for the six months ended 30 June 2016. Operational highlights …
Wanda Technology Selected by 24Hr HomeCare
RNS Number : 6195K NetScientific PLC 23 September 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”) Wanda Technology Selected by 24Hr HomeCare to Improve Care and Reduce Hospital Re-admissions London, UK – 23 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, Wanda, has been selected by the Los Angeles-based 24Hr HomeCare to …
Glycotest strengthens IP portfolio
RNS Number : 4947J NetScientific PLC 12 September 2016 (“NetScientific” or the “Company” or the “Group”) Glycotest Strengthens Intellectual Property Portfolio with Japanese Patent Grant Japanese patent joins five other patents to add significant protection to core technology London, UK – 12 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that one of its portfolio companies, Glycotest, …
Wanda Appoints Digital Health Non-Exec Director
RNS Number : 2460J NetScientific PLC 08 September 2016 (“NetScientific” or the “Company” or the “Group”) Wanda Strengthens its Board with Digital Health Non-Executive Director Derek Newell brings decades of digital health expertise London, UK – 08 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that one of its portfolio companies, Wanda, has appointed a new Non-Executive …
Notice of Interim Results
RNS Number : 0032J NetScientific PLC 06 September 2016 (“NetScientific” or the “Company” or the “Group”) Notice of Interim Results London, UK – 6 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that it will report its interim results for the six months ended 30 June 2016 on Tuesday 27 September2016. An analyst presentation will …
Wanda Launches First Consumer App
RNS Number : 6055H NetScientific PLC 19 August 2016 (“NetScientific” or the “Company” or the “Group”) myWanda Mobile App Launches to Help Women Manage Heart Health with Personalized Guidance myWanda is Wanda’s first consumer app, making it easier for women to receive support, education and guidance on heart health London, UK – 19 August 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic …
Vortex Biosciences Appoints Experts to New SAB
RNS Number : 5166H NetScientific PLC 18 August 2016 (“NetScientific” or the “Company” or the “Group”) Vortex Biosciences Appoints Leading Experts to Newly Formed Scientific Advisory Board London, UK – 18 August 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that its portfolio company Vortex Biosciences has made a number of appointments to its newly formed Scientific …
Vortex Licenses Patents From Harvard University
RNS Number : 0608G NetScientific PLC 03 August 2016 (“NetScientific” or the “Group”) Vortex Biosciences Announces Exclusive License of Patents for Novel Cell Electroporation Technology From Harvard University London, UK – 3 August 2016 – NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its portfolio company Vortex Biosciences has announced the exclusive license of a series of …
Change of Adviser
RNS Number : 4527F NetScientific PLC 28 July 2016 (“NetScientific” or the “Company” or the “Group”) Change of Adviser London, UK – 28 July 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as Nominated Adviser and Broker to the Company with immediate effect. – Ends – …
Wanda Appoints Medical Director
RNS Number : 3124F NetScientific PLC 27 July 2016 (“NetScientific” or the “Company” or the “Group”) Wanda Names Dr. Suzanne Steinbaum, Renowned Cardiologist and Women’s Heart Health Advocate, as Medical Director Dr. Steinbaum joins Wanda’s mission to create personalized health guidance and accountability using advanced predictive analytics, behavioural science, and mobile technologies. London, UK – 27 July 2016 – NetScientific plc (“NetScientific”, …
A to Z Home Health Care selects Wanda technologies
RNS Number : 9291E NetScientific PLC 22 July 2016 (“NetScientific” or the “Company” or the “Group”) A to Z Home Health Care selects Wanda’s home-centred care technologies to enhance patient outcomes California-based firm will deploy Wanda’s science-driven solutions in multiple languages to accommodate multi-cultural clients London, UK – 22 July 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology …
Grant of Options to Director
RNS Number : 2799C NetScientific PLC 27 June 2016 (“NetScientific” or the “Company” or the “Group”) Grant of Options to Director London, UK – 27th June 2016 – NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announced that on 24th June 2016, options over ordinary shares of 5p each were granted to Ian Postlethwaite and Stephen Smith as detailed below. …
Results of Annual General Meeting
RNS Number : 3020B NetScientific PLC 15 June 2016 (“NetScientific” or the “Company” or the “Group”) Results of Annual General Meeting London, UK – 15th June 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that all resolutions proposed at today’s Annual General Meeting, were duly passed. NetScientific has over the past year undergone a transformation, with …
Vortex Biosciences appoints Chairman of SAB
RNS Number : 0706B NetScientific PLC 14 June 2016 (“NetScientific” or the “Company” or the “Group”) Vortex Biosciences appoints Dr. Massimo Cristofanilli as Chairman of newly formed Scientific Advisory Board London, UK – 14 June 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, notes its portfolio company Vortex Biosciences has appointed Dr. Massimo Cristofanilli as Chairman of its …
NetScientific hosts Capital Markets Day
RNS Number : 0709B NetScientific PLC 14 June 2016 14 June 2016 NetScientific plc (“NetScientific” or the “Group”) NetScientific hosts Capital Markets Day to outline its strategy and showcase its portfolio of assets London, UK – 14 June 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is today hosting a Capital Markets Day in London to outline the comprehensive …
Confirmed Start Date for Ian Postlethwaite as CFO
RNS Number : 8030A NetScientific PLC 10 June 2016 (“NetScientific” or the “Company” or the “Group”) Netscientific Confirms Start Date for Ian Postlethwaite as CFO London, UK – 10 June 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to confirm that further to the Company’s announcement of his appointment on 5th April 2016, new Chief …
Portfolio PDS Biotechnology presents at BIO 2016
RNS Number : 3753A NetScientific PLC 07 June 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Portfolio PDS Biotechnology presents at BIO 2016 NetScientific makes further investment in PDS Biotechnology London, UK – 7 June 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased to note that its therapeutics portfolio company, PDS Biotechnology, will today be presenting …
Notice of AGM
RNS Number : 9816Y NetScientific PLC 23 May 2016 NetScientific (“NetScientific” or the “Company” or the “Group”) Notice of AGM and Annual Report & Accounts London, UK – 23 May 2016 – NetScientific plc (AIM:NSCI), the transatlantic healthcare technology group announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2015 and …
NetScientific’s Vortex presents data at AACR
RNS Number : 4509V NetScientific PLC 18 April 2016 NetScientific (“NetScientific” or the “Company” or the “Group”) NetScientific portfolio company Vortex Biosciences introduces novel fully automated circulating tumour cell enrichment instrument VTX-1 at AACR London, UK – 18 April 2016 – NetScientific plc (AIM:NSCI), the transatlantic healthcare technology group, notes that its portfolio company, Vortex Biosciences, will preview VTX-1, a fully …
PDS Biotechnology Reports Positive Phase 1 Results
RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …
Annual Financial Report
RNS Number : 4343U NetScientific PLC 07 April 2016 7 April 2016 NetScientific plc (“NetScientific” or the “Group”) NetScientific Full Year Results year ended 31 December 2015 London, UK – 7 April 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, announces its audited Full Year results for the year ended 31 December 2015. Operational highlights: · Appointment …
Netscientific Appoints Ian Postlethwaite as CFO
RNS Number : 1367U NetScientific PLC 05 April 2016 (“NetScientific” or the “Company” or the “Group”) Netscientific Appoints Ian Postlethwaite as Chief Financial Officer London, UK – 5th April 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and …
ProAxsis Forms Scientific Advisory Board
RNS Number : 4656T NetScientific PLC 30 March 2016 (“Netscientific” or the “Group”) ProAxsis Forms Scientific Advisory Board to Provide Strategic Guidance London, UK – 30 March 2016 – NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Diagnostics portfolio company, ProAxsis, has announced the formation of a Scientific Advisory Board to support ProAxsis in the development of its …
Notice of Results
RNS Number : 1205T NetScientific PLC 24 March 2016 (“NetScientific” or the “Company” or the “Group”) Notice of Results London, UK – 24 March 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that it will report its final results for the 12 months ended 31 December 2015 on 07 April 2016. An analyst presentation will be held …
Wanda Forms Scientific Advisory Board
RNS Number : 2148S NetScientific PLC 16 March 2016 (“NetScientific” or the “Group”) Wanda Forms Scientific Advisory Board to Provide Strategic Guidance London, UK – 16 March 2016 – NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and …
Adoption of reduced disclosure framework
RNS Number : 2859R NetScientific PLC 07 March 2016 NetScientific plc Adoption of the reduced disclosure framework within Financial Reporting Standard (FRS) 102 London, UK – 7th March 2016 – NetScientific plc (“NetScientific”. AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announces that following the publication of FRS 100 ‘Application of Financial Reporting Requirements’ by the Financial Reporting Council, it is required to …
Vortex co-founder receives US Presidential award
RNS Number : 6459Q NetScientific PLC 01 March 2016 NetScientific plc Vortex BioSciences co-founder receives US Presidential award for groundbreaking “Liquid Biopsy” technique London, UK – 1 March 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group notes its operating subsidiary, Vortex Biosciences’ (‘Vortex’) announcement about its co-founder receiving the US Presidential Early Career Award …
Wanda and Dignity Health launch OncoVerse platform
RNS Number : 3883Q NetScientific PLC 29 February 2016 NetScientific plc Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform – OncoVerse™ London, UK – 29 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of …
NetScientific appoints Prof. Stephen Smith as NED
RNS Number : 2646P NetScientific PLC 17 February 2016 NetScientific plc NetScientific appoints Professor Stephen Smith as Non-Executive Director London, UK – 17 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees. …
PDS Biotechnology partners with NCI
RNS Number : 5158O NetScientific PLC 09 February 2016 NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …
Grant of Options to Director
RNS Number : 4149O NetScientific PLC 08 February 2016 NetScientific plc Grant of Options to Director London, UK – 8 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced that on 4 February 2016, options over a total of 200,000 ordinary shares of 5p each were granted to Francois Martelet. Director …
Directorate Change
RNS Number : 9451M NetScientific PLC 26 January 2016 NetScientific plc Board Change London, UK – 26 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced the resignation from the board of Peter Thoms, Chief Financial Officer. Peter leaves the company in order to pursue new challenges, particularly in the technology sector. …
PDS Biotechnology adds drug development executives
RNS Number : 4379M NetScientific PLC 20 January 2016 NetScientific plc PDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes London, UK – 20 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, …
Glycotest Inc. appoints medical advisory board
RNS Number : 9237K NetScientific PLC 06 January 2016 NetScientific plc NetScientific portfolio company, Glycotest Inc., appoints world leading medical advisory board chaired by David Chernoff, M.D. London, UK – 6 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints a medical advisory board of leading liver experts …
WANDA signs contract with HRS
RNS Number : 6412K NetScientific PLC 04 January 2016 NetScientific plc WANDA signs contract with leading US home nursing and therapy service provider, HRS, to provide better care for patients with chronic conditions London, UK – 4 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that portfolio company, WANDA …
Lawrence Cohen appointed as CEO of Glycotest Inc.
RNS Number : 1865J NetScientific PLC 16 December 2015 NetScientific appoints diagnostics leader Lawrence Cohen as CEO of Glycotest Inc. London, UK – 16 December 2015 – NetScientific plc (AIM: NSCI, “NetScientific” or the “Group”), the transatlantic biomedical and healthcare technology group, today announces the appointment of Lawrence ‘Larry’ Cohen as CEO of its portfolio company, Glycotest, effective from 4 January 2016. …
Appointment of Gene Walther as Vortex CEO
RNS Number : 8771I NetScientific PLC 14 December 2015 NetScientific plc Ex Novartis Diagnostics president, Gene Walther is appointed CEO of Vortex BioSciences and NetScientific’s Head of Diagnostics Board Change London, UK – 14 December 2015 – NetScientific plc (AIM: NSCI, ‘NetScientific’ or the ‘Group’), the transatlantic biomedical and healthcare technology group, continues its restructuring towards a sector franchise model with …
ProAxsis’ ProteaseTag™ research update
RNS Number : 8155H NetScientific PLC 03 December 2015 NetScientific plc ProAxsis’ ProteaseTag™ technology shown to effectively monitor patients with chronic obstructive pulmonary disease London, UK – 3 December 2015 – Further to the announcement on 30 November 2015, NetScientific plc’s (AIM: NSCI, “NetScientific” or the “Group”) portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, will present new data …
ProAxsis presents data to validate its immunoassay
RNS Number : 2866H NetScientific PLC 30 November 2015 NetScientific plc ProAxsis presents new data to validate its ProteaseTag™ Active NE Immunoassay in chronic obstructive pulmonary disease patients London, UK – 30 November 2015 – NetScientific plc’s (“NetScientific” or the “Group”, AIM: NSCI) portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, will present new data that validates the …
Issue of Equity
RNS Number : 7571F NetScientific PLC 16 November 2015 NetScientific PLC (“NetScientific” or the “Group”) London, UK – 16 November 2015: NetScientific PLC (AIM: NSCI.L), a transatlantic biomedical healthcare group, announces that it will today apply to admit, in total, 54,167 ordinary shares of 5p each to trading on AIM. Admission is expected on 20 November 2015 and these shares will rank pari …
Holding(s) in Company
RNS Number : 2698F NetScientific PLC 11 November 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying financial …
Grant of Options
RNS Number : 1137F NetScientific PLC 10 November 2015 NetScientific PLC (“NetScientific” or the “Group”) Grant of Options to Director London, UK – 10 November 2015: NetScientific plc (AIM:NSCI), a transatlantic biomedical healthcare group, announces that on 9 November 2015, options over a total of 359,020 Ordinary Shares of 5p each were granted to Francois Martelet. Director Position Number of Options Granted …
Result of General Meeting
RNS Number : 8824E NetScientific PLC 06 November 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. …
Result of Placing and Further Allotment of Shares
RNS Number : 7886E NetScientific PLC 06 November 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. …
Holding(s) in Company
RNS Number : 4417E NetScientific PLC 03 November 2015 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): …
Posting of Circular
RNS Number : 9468C NetScientific PLC 21 October 2015 NetScientific plc (“NetScientific” or the “Company”) Posting of Circular 21 October 2015 Further to the announcement made by the Company on 1 October 2015, NetScientific announces that a Circular has today been published and posted to shareholders in relation to the proposed placing to raise approximately £18.0 million (before expenses), the additional …
Half Yearly Report
RNS Number : 8339A NetScientific PLC 01 October 2015 NetScientific plc (‘NetScientific or the ‘Company’ or the ‘Group’) Half Year Results for the six months ended 30 June 2015 London, UK – 1 October 2015: NetScientific (AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced its half year results for the six months ended 30 June 2015. …
Proposed Placing and Fund Raising to raise GBP 20m
RNS Number : 8342A NetScientific PLC 01 October 2015 THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO …
Divestment of Shareholding in Frontier BioSciences
RNS Number : 4497Z NetScientific PLC 18 September 2015 NetScientific plc Divestment of shareholding in Frontier BioSciences and realignment of resources towards our primary portfolio London, UK – 18 September 2015 – NetScientific plc (“NetScientific” or “the Company”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, has agreed to sell NetScientific UK Limited’s (“NS UK”) 49.9% holding in Frontier BioSciences …
Holding(s) in Company
RNS Number : 2576Z NetScientific PLC 16 September 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying …
Vortex BioSciences granted critical patent
RNS Number : 0312Z NetScientific PLC 15 September 2015 NetScientific plc Vortex BioSciences granted critical patent for its Liquid Biopsy technology London, UK – 15 September 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that one of its key portfolio companies, Vortex BioSciences Inc., has been granted a critical patent on its …
Steve Curd appointed as CEO of Wanda
RNS Number : 5652Y NetScientific PLC 09 September 2015 NetScientific plc NetScientific announces the key appointment of Steve Curd as CEO of Wanda, Inc. London, UK – 9 September 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces the appointment of Steve Curd as CEO of its portfolio company, Wanda, and …
Divestment of non-core assets to align portfolio
RNS Number : 3824V NetScientific PLC 07 August 2015 NetScientific plc NetScientific divests non-core assets to align its healthcare portfolio London, UK – 7 August 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that as part of an ongoing review of its portfolio, it has started to divest certain projects that …
ProAxsis launches first-in-class ProteaseTag™ test
RNS Number : 9521U NetScientific PLC 04 August 2015 NetScientific plc ProAxsis launches first-in-class ProteaseTagTM test for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease London, UK – 4 August 2015 – NetScientific portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, has officially launched its proprietary first-in-class ProteaseTag™ immunoassay kits to research labs and announces its first two customer orders, …
Key patent granted for Glucosense’s technology
RNS Number : 0582T NetScientific PLC 15 July 2015 NetScientific plc Significant European patent granted on Glucosense Diagnostics technology London, UK – 15 July 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, highlights University of Leeds’ announcement about its jointly funded portfolio company, Glucosense Diagnostics (Glucosense). Today the award of …
Results of Annual General Meeting
RNS Number : 8379Q NetScientific PLC 22 June 2015 NetScientific plc Results of Annual General Meeting London, UK – 22 June 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, announces that all resolutions proposed at today’s Annual General Meeting have been duly passed. As previously announced, Francois Martelet, the …
AGM Statement
RNS Number : 7804Q NetScientific PLC 22 June 2015 NetScientific plc Annual General Meeting London, UK – 22 June 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, is holding its Annual General Meeting (AGM) today at 11am. Ahead of this meeting Chairman, Sir Richard Sykes, will make the following comments: “2015 has been transformational for the …
Notification of Major Interest in Shares
RNS Number : 4404P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …
Notification of Major Interest in Shares
RNS Number : 4401P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …
Notification of Major Interest in Shares
RNS Number : 4400P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …
Notification of Major Interest in Shares
RNS Number : 4038P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying financial …
Notification of Major Interest in Shares
RNS Number : 4034P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NETSCIENTIFIC PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights YES An acquisition or disposal of qualifying financial …
PDS Biotechnology reports positive Phase I results
RNS Number : 5095O NetScientific PLC 28 May 2015 NetScientific plc (“NetScientific” or the “Group”) PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy London, UK – 28 May 2015 – NetScientific (AIM: NSCI) notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in …
Notice of AGM and Annual Report & Accounts
RNS Number : 4055N NetScientific PLC 18 May 2015 NetScientific plc (“NetScientific” or the “Group”) Annual Report and Accounts London, UK – 18 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2014 and Notice of Annual …
Capital Markets Day
RNS Number : 2602N NetScientific PLC 15 May 2015 NetScientific plc (“NetScientific” or the “Group”) Capital Markets Day London, UK – 15 May 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, is holding a Capital Markets Day for institutional investors and analysts today in London. The event includes a presentation on NetScientific’s refined strategy which has …
Dr. Francois R. Martelet appointed as CEO
RNS Number : 7136M NetScientific PLC 11 May 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific appoints Dr. François R. Martelet as Chief Executive Officer London, UK – 11 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces the appointment of Dr François R. Martelet as Chief Executive Officer and Board Director. Dr. Martelet will join …
NetScientific invests in Neumitra
RNS Number : 4149M NetScientific PLC 07 May 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific invests in wearable digital health company, Neumitra London, UK – 7 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced its investment in Neumitra, a digital health company, developing wearable devices and smart software applications for the real-time management of …
NetScientific Forms New Digital Health Company
RNS Number : 9480L NetScientific PLC 01 May 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific forms digital health company with US hospital group, Meridian Health Triventis Health LLC will commercialise advanced patient management solutions 1 May 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, has formed a new digital health sales and marketing subsidiary company, Triventis Health LLC …
NetScientific Capital Markets Day
RNS Number : 6699L NetScientific PLC 29 April 2015 NetScientific plc (“NetScientific” or the “Group”) Capital Markets Day London, UK – 29 April 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, will be holding a Capital Markets Day on Friday 15 May 2015 at 10.30am – 3.00pm in London to provide an update on the …
Change of Adviser
RNS Number : 0844J NetScientific PLC 01 April 2015 NetScientific plc Appointment of Adviser London, UK – 1 April 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, announces that it has appointed Investec Bank plc as its Nominated Adviser and sole Broker with immediate effect. -Ends- About NetScientific NetScientific is a biomedical and healthcare technology group …
Significant Progress in core Portfolio Companies
RNS Number : 2522I NetScientific PLC 24 March 2015 NetScientific plc (‘NetScientific’ or the ‘Group’) NetScientific Full Year results: Significant Progress in core Portfolio Companies Wanda Health and Vortex BioSciences. First commercial launches expected during 2015 London, UK – 24 March 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare group, announces its results for the year ended 31 December 2014. Highlights …
Notice of Full Year Results
RNS Number : 0638I NetScientific PLC 20 March 2015 NetScientific plc (“NetScientific” or the “Group”) Notice of Full Year Results London, UK – 20 March 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, will announce its full year results for the year ended 31 December 2014 on Tuesday 24 March 2015. A presentation for analysts will be held …
Appointment of Non-Executive Director
RNS Number : 9575F NetScientific PLC 26 February 2015 NetScientific plc (“NetScientific” or the “Group”) Appointment to the Board NetScientific appoints Jonathan Paisner as Non-Executive Director 26 February 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group is pleased to announce that Jonathan Paisner will join the Board with immediate effect as a non-executive director. Jonathan is …
Directorate Change
RNS Number : 4483C NetScientific PLC 16 January 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific announces departure of Chief Executive Officer 16 January 2015: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announces that Farad Azima has been removed from the positions of Chief Executive Officer and a Director of NetScientific with immediate effect. The Board has unanimously agreed …
NetScientific teams up with KU Leuven
RNS Number : 5259B NetScientific PLC 07 January 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific teams up with KU Leuven on research programmes in early cancer detection, epigenomic analysis and fiber-optics diagnostics 7th January 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced that it has entered into three research programmes with KU Leuven in Belgium. The …
NetScientific invests in DName-iT
RNS Number : 5253B NetScientific PLC 07 January 2015 NetScientific plc (“NetScientific” or the “Group”) NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing 7th January 2015: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced its investment in DName-iT NV (“DName-iT”) a spin-out from KU Leuven in Belgium As a subsidiary company of NetScientific, …
NetScientific invests in PDS Biotechnology
RNS Number : 7136Z NetScientific PLC 15 December 2014 NetScientific plc (‘NetScientific’ or ‘the Group’) NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology 15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’). PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more …
NetScientific enters into alliance with Healthbox
RNS Number : 4502Z NetScientific PLC 11 December 2014 NetScientific plc (‘NetScientific’ or ‘the Group’) NetScientific enters into an alliance with Healthbox to invest in new early-stage healthcare companies 11 December 2014: NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced entering into an alliance with Healthbox, a leading healthcare business accelerator, to support the development of early-stage healthcare …
NetScientific invests in Breakout Labs’ portfolio
RNS Number : 0499Z NetScientific PLC 08 December 2014 NetScientific plc (‘NetScientific’ or ‘the Group’) NetScientific invests in Breakout Labs’ portfolio company EpiBone 8 December 2014: NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced it has made an investment in EpiBone, a revolutionary bone reconstruction company that allows patients to “grow their own bone”. It is the Group’s fourth …
Holding(s) in Company
RNS Number : 2346X NetScientific PLC 17 November 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii netScientific Group 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights Yes An acquisition or disposal of qualifying …
Holding(s) in Company
RNS Number : 2097X NetScientific PLC 17 November 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …
Subsidiary, Glycotest collaboration with Oncimmune
RNS Number : 3461T NetScientific PLC 03 October 2014 NetScientific plc (‘NetScientific’ or ‘the Group’) NetScientific’s subsidiary, Glycotest Begins a New Research Collaboration with Oncimmune Application of Combined Diagnostic Technologies Aimed at Improving Early Detection of Liver Cancer 3 October 2014: NetScientific (AIM: NSCI), the global biomedical and healthcare technology group today announces its portfolio company Glycotest, Inc. has entered …
Half Yearly Report
RNS Number : 3136S NetScientific PLC 23 September 2014 NetScientific plc (‘NetScientific’ or ‘the Company’ or ‘the Group’) Half-Yearly Report 23 September 2014: NetScientific (AIM: NSCI), the global biomedical and healthcare technology group today announces its half yearly report for the six months ended 30 June 2014. Highlights § Significant progress made in advancing the technologies in …
Notice of Half Yearly Report
RNS Number : 9340R NetScientific PLC 17 September 2014 NetScientific plc (‘NetScientific’ or ‘the Company’) Notification of Half Yearly Report Date NetScientific (AIM: NSCI), the biomedical and healthcare technology investment group, will announce its half yearly report for the six months ended 30 June 2014 on Tuesday, 23 September 2014. A presentation for …
NetScientific announces shareholder name change
RNS Number : 6569N NetScientific PLC 29 July 2014 NetScientific announces significant shareholder name change NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, has been informed by one of the Group’s significant shareholders, Quantadyne Limited, which owns 9.6% of the Company’s equity, that it has changed its name to White Mustard Investments. For further information, please contact: …
TR1 – Notification of Major Interest in Shares
RNS Number : 8531M NetScientific PLC 21 July 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights Yes An acquisition or disposal of qualifying …
TR1 – Notification of Major Interest in Shares
RNS Number : 1064M NetScientific PLC 11 July 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …
Notification of Major Interest In Shares
RNS Number : 5298L NetScientific PLC 04 July 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …
Research Programme in DNA Sequencing
RNS Number : 1276L NetScientific PLC 02 July 2014 NetScientific plc (‘NetScientific’ or the ‘Group’) Research Programme in DNA Sequencing NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with …
NetScientific plc
RNS Number : 1943J NetScientific PLC 09 June 2014 NetScientific plc NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘the Company’), the biomedical and healthcare technology investment group, today announces that it has entered into a new service agreement with Peter Thoms, a director of the Company, terminable on six months’ notice by either party. Following this, the Remuneration Committee has today awarded him options to …
AGM Statement
RNS Number : 5261H NetScientific PLC 20 May 2014 NetScientific plc AGM Statement At the Company’s Annual General Meeting to be held today at 11.30 a.m. the Chairman, Sir Richard Sykes, will make the following statement to shareholders: “I am pleased to report that the year has started well. We have continued to invest in our key subsidiaries, with particular focus on …
Result of AGM
RNS Number : 6276H NetScientific PLC 20 May 2014 NetScientific plc Result of AGM NetScientific is pleased to announce that at its Annual General Meeting held earlier today all resolutions proposed in the Notice of the Meeting were duly passed. For further information, please contact: Liberum (Nomad & Broker) Chris Bowman / Christopher Britton / Thomas Bective Tel: …
Announcement of research agreement with Harvard
RNS Number : 3950H NetScientific PLC 19 May 2014 NetScientific announces research agreement with Harvard University NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce that Vortex, its Palo Alto based spinout, has signed an agreement with the Rowland Institute at Harvard University. Under the research agreement, the Rowland Institute will explore …
Posting of Annual Report and Notice of AGM
RNS Number : 5906G NetScientific PLC 08 May 2014 NetScientific plc (‘NetScientific’ or the ‘Group’) Posting of Annual Report and Notice of AGM 8 May 2014 NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, announces that the Group’s Report and Accounts, for the period ended 31 December 2013, and Notice of AGM have been posted to shareholders. A …
NetScientific Partners with Breakout Labs
RNS Number : 1817D NetScientific PLC 26 March 2014 NetScientific Partners with Peter Thiel’s Breakout Labs to Increase Support for Companies at the Forefront of Scientific Innovation NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce a strategic alliance with the San Francisco-based Breakout Labs, Peter Thiel’s revolving philanthropic fund that supports …
Preliminary results
RNS Number : 6281C NetScientific PLC 19 March 2014 NetScientific plc (‘NetScientific’ or the ‘Group’) Preliminary results for the 12 months ended 31 December 2013 19 March 2014 NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, has published its results for the year ended 31 December 2013. Highlights § £30.0 million (net of costs £28.6) …
Notice of Results
RNS Number : 2763C NetScientific PLC 13 March 2014 Netscientific plc (‘Netscientific’ or ‘the Company’) Notification of Results Netscientific, the biomedical and healthcare technology investment group, will announce its full year results for the year ended 31 December 2013 on Wednesday 19 March 2014. A presentation for analysts, hosted by the management team, will be held at 9:00am GMT on Wednesday 19th March 2014. …
NetScientific invests in ProAxsis
RNS Number : 7384A NetScientific PLC 24 February 2014 24 February 2014 NetScientific plc (“NetScientific” or the “Group”) NetScientific announces investment in ProAxsis NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology commercialisation and investment group, is pleased to announce its investment in ProAxsis Ltd (‘ProAxsis’), a spin-out from Queen’s University Belfast, which was named …
Director Dealings
RNS Number : 1835P NetScientific PLC 30 September 2013 30 September 2013 NetScientific plc (“NetScientific” or the “Group”) Director Dealings NetScientific, the healthcare medical technology company, announces that on 27 September 2013 it received notification that, on 27 September 2013, Barry Wilson, Non Executive Director of the Group, purchased 6,150 ordinary shares of 5p each in the capital of the Group …
Interim results for six months ended 30 June 2013
RNS Number : 0585P NetScientific PLC 27 September 2013 NetScientific plc (‘NetScientific’ or the ‘Group’) Interim results for the six months ended 30 June 2013 27 September 2013 NetScientific (AIM:NSCI), the healthcare medical technology company, is pleased to announce its maiden unaudited interim results for the six months ended 30 June 2013. Financial Highlights · Pre-tax loss for the period of £1,040k (H1 …
Admission to AIM and First Day of Dealings
RNS Number : 0184O NetScientific PLC 16 September 2013 NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR THE REPUBLIC OF IRELAND OR IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION For Immediate Release 16 September 2013 NetScientific plc (“NetScientific” or the “Group”) …
NetScientific plc
6 Bevis Marks
1st floor, Bury Court
London
EC3A 7BA
Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net
copyright
RNS Announcements Archives - NetScientific